Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
phase 3
Biotech
Cytokinetics’ ph. 3 cardio win sends stock soaring
Aficamten bested a standard-of-care beta blocker in a phase 3 heart disease test, bolstering the asset's blockbuster expectations.
Darren Incorvaia
Sep 2, 2025 2:05pm
Spine BioPharma misses primary endpoint in back pain phase 3
Aug 1, 2025 10:24am
Merck wades deeper into HIV PrEP waters with pair of trials
Jul 14, 2025 1:12pm
UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss
Jul 8, 2025 10:17am
FDA delays force Daré to shelve phase 3 plans: WSJ
Apr 17, 2025 3:03pm
Orca prepares to make market plunge after phase 3 win
Mar 17, 2025 7:00am
